Loading
A phase 2 trial of Tadalafil 5mg in prostate cancer, run by Biozeus Biopharmaceutical S.A., now recruiting.
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients is a phase 2 interventional study registered as NCT05558007 by Biozeus Biopharmaceutical S.A., with 72 participants planned, started 2023-11-22 and due to reach its primary completion in 2024-12-31. Interventions recorded: Tadalafil 5mg, BZ371A, Oral Placebo and Topical Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/